Deals in Depth: October 2010
Teaming up for the sixth time, Exelixis penned a $545 million deal with BMS for early-stage type 2 diabetes and inflammation candidates. Stryker/Boston Scientific's neurovascular business and St. Jude/AGA Medical were the two billion-dollar acquisitions in devices. Biopharma financing hugely increased to over $2 billion in October. Device fundraising reached $280 million, almost exactly as much as September's total.
You may also be interested in...
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
Not Your Grandfather’s CAPA: Case For Quality Pilot Gives Corrective And Preventive Action A Facelift
Big changes are afoot when it comes to CAPA. Ten medtech manufacturing sites are playing in a pilot program that uses a novel framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach that separates higher-risk events from others that don’t need to be elevated to the level of a traditional CAPA. Medtronic quality/regulatory expert Kathryn Merrill weighs in.
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.